Scarica l'app Stockscreener
2.345
3.96%
0.085
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.26
Aprire:
$2.27
Volume 24 ore:
118.06K
Relative Volume:
1.21
Capitalizzazione di mercato:
$91.73M
Reddito:
$2.70M
Utile/perdita netta:
$5.53M
Rapporto P/E:
-4.598
EPS:
-0.51
Flusso di cassa netto:
$-10.55M
1 W Prestazione:
+0.63%
1M Prestazione:
+0.20%
6M Prestazione:
+1.71%
1 anno Prestazione:
+9.79%
Intervallo 1D:
$2.27
$2.355
Intervallo di 1 settimana:
$2.13
$2.355
Portata 52W:
$2.00
$3.67
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Nome
Oramed Pharmaceuticals Inc
Settore
Industria
Telefono
646-844-1164
Indirizzo
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Confronta ORMP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ORMP | 2.345 | 91.73M | 2.70M | 5.53M | -10.55M | -0.51 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.10 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.29 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.52 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Iniziato | Canaccord Genuity | Buy |
| 2021-02-09 | Iniziato | National Securities | Buy |
| 2020-12-03 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-11 | Iniziato | Aegis Capital | Buy |
| 2019-09-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-12-11 | Ripresa | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Reiterato | FBR Capital | Outperform |
| 2015-12-01 | Reiterato | H.C. Wainwright | Buy |
| 2015-11-19 | Iniziato | FBR Capital | Outperform |
| 2015-04-13 | Ripresa | MLV & Co | Buy |
| 2014-01-30 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Reiterato | Aegis Capital | Buy |
| 2014-01-08 | Iniziato | MLV & Co | Buy |
| 2013-12-03 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Oramed Pharmaceuticals Inc Borsa (ORMP) Ultime notizie
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Passes Below 200-Day Moving AverageShould You Sell? - MarketBeat
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock Holdings Lifted by BML Capital Management LLC - MarketBeat
Type 1 Diabetes Market Future Business Opportunities 2024-2031 - openPR
Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M - Simply Wall St
Oramed Announces Additional $1M Payment on Tranche A Note By Investing.com - Investing.com South Africa
Oramed Announces Additional $1M Payment on Tranche A Note - Investing.com India
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Buy at StockNews.com - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to "Hold" at StockNews.com - MarketBeat
ORAMED PHARMACEUTICALS INC. Refinances with New Securities Purchase Agreement - MarketBeat
Oramed Pharmaceuticals Reinforces Scilex Financial Ties - TipRanks
Scilex Holding extends payment deadline in Oramed agreement - Investing.com India
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - PR Newswire
Scilex Holding Company Announces Signing of a $50 Million - GlobeNewswire
Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Buy by StockNews.com - MarketBeat
Tranche Update on Oramed Pharmaceuticals Inc.'s Equity Buyback Plan announced on June 26, 2024. - Marketscreener.com
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Shares Bought by Murchinson Ltd. - MarketBeat
Oramed signs $11.5 million deal for clinical trial services By Investing.com - Investing.com South Africa
Oramed signs $11.5 million deal for clinical trial services - Investing.com
Non-Alcoholic Steatohepatitis Pipeline Insights 2024: - openPR
Non-Alcoholic Steatohepatitis Pipeline Insights 2024: Therapies, Clinical Trials, and MOA, ROA by DelveInsight | Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed - Barchart
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to Hold - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World
Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat
Scilex Holding agrees to payment terms with Oramed Pharmaceuticals - Investing.com India
Oramed Pharmaceuticals (ORMP) Price Target Increased by 57.50% to 3.21 - MSN
Moors & Cabot Inc. Buys 164 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Oriole Resources (LON:ORR) Shares Down 2.3% - Defense World
Sidoti Csr Weighs in on Orion Group Holdings, Inc.’s Q3 2024 Earnings (NYSE:ORN) - Defense World
Oral Biologics Market 2024-2031 Industry Size Forecast: Growth - openPR
O'Reilly Automotive, Inc. (NASDAQ:ORLY) Position Raised by E Fund Management Co. Ltd. - MarketBeat
BMO Capital Markets analysts downgrades a Market perform rating for Ionis Pharmaceuticals Inc (IONS) - Knox Daily
Wealthspire Advisors LLC Buys 12 Shares of O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
OMIC’s Market Whiplash: -10.31% YTD Decline, 69.47% Rise in 30 Days - The InvestChronicle
Ashton Thomas Private Wealth LLC Takes Position in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
O’Reilly Automotive, Inc. (NASDAQ:ORLY) Shares Purchased by Acadian Asset Management LLC - Defense World
Private Advisor Group LLC Has $2.56 Million Stake in O’Reilly Automotive, Inc. (NASDAQ:ORLY) - Defense World
Research Analysts Set Expectations for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP) - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to “Hold” - Defense World
Comprehensive Study of Oral Biologics Market 2024-2031 - openPR
Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded to "Hold" at StockNews.com - MarketBeat
Oramed Pharmaceuticals’ (ORMP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Neutral rating on Oramed amid ongoing NMPA review - Investing.com India
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Brokers Offer Predictions for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP) - MarketBeat
ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, Buybacks - MSN
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by StockNews.com to Buy - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below Two Hundred Day Moving Average of $2.58 - MarketBeat
Future Scope of Oral Biologics Market Overall Study Report - openPR
Oramed Pharmaceuticals Inc Azioni (ORMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):